

# SCIENTIFIC REPORTS



OPEN

## *Helicobacter pylori* colonization and obesity – a Mendelian randomization study

Wouter J. den Hollander<sup>1</sup>, Linda Broer<sup>2</sup>, Claudia Schurmann<sup>3,4</sup>, David Meyre<sup>5,6</sup>, Caroline M. den Hoed<sup>1</sup>, Julia Mayerle<sup>7</sup>, Albert Hofman<sup>8,10</sup>, Georg Homuth<sup>9</sup>, André G. Uitterlinden<sup>2,8</sup>, Markus M. Lerch<sup>7</sup> & Ernst J. Kuipers<sup>1,2</sup>

Obesity is associated with substantial morbidity, costs, and decreased life expectancy, and continues to rise worldwide. While etiological understanding is needed for prevention, epidemiological studies indicated that colonization with *Helicobacter pylori* (*H. pylori*) may affect body mass index (BMI), but with inconsistent results. Here, we examine the relationship between *H. pylori* colonization and BMI/obesity. Cross-sectional analyses were performed in two independent population-based cohorts of elderly from the Netherlands and Germany ( $n = 13,044$ ). Genetic risk scores were conducted based on genetic loci associated with either *H. pylori* colonization or BMI/obesity. We performed a bi-directional Mendelian randomization. Meta-analysis of cross-sectional data revealed no association between anti-*H. pylori* IgG titer and BMI, nor of *H. pylori* positivity and BMI. Anti-*H. pylori* IgG titer was negatively associated with obesity (OR 0.99972; 95% CI 0.99946–0.99997,  $p = 0.03$ ) and with obesity classes (Beta  $-6.91 \bullet 10^{-5}$ ; 95% CI  $-1.38 \bullet 10^{-4}$ ,  $-5.49 \bullet 10^{-7}$ ,  $p = 0.048$ ), but the magnitude of these effects was limited. Mendelian randomization showed no causal relation between *H. pylori* genetic risk score and BMI/obesity, nor between BMI or obesity genetic risk scores and *H. pylori* positivity. This study provides no evidence for a clinically relevant association between *H. pylori* and BMI/obesity.

The prevalence of obesity rises worldwide. This is associated with significant morbidity, costs, and decreased life expectancy. The latter can be reduced with 8–13 years<sup>1</sup>, which results in a huge economic burden<sup>2</sup>. The causes of obesity are diverse and include excessive energy intake, lack of physical activity, but also culprits such as stress, lack of sleep, or exposure to chemical endocrine disruptors<sup>3</sup>. There is increasing evidence from mouse as well as human studies that shows that the gut microbiome may play an important role in energy balance<sup>4</sup>. Modern lifestyle, and the widespread use of antibiotics may affect the composition of our microbiome, which may have consequences for our health<sup>5</sup>.

In this context, *Helicobacter pylori* (*H. pylori*), is of relevance. This Gram-negative, spiral-shaped, gastric bacterium is gradually disappearing in Western populations<sup>5,6</sup>. *H. pylori* colonization is virtually always associated with chronic active gastritis, which can have various effects. This includes interference with gastric hormone regulation, including ghrelin and leptin. Both have multiple roles in energy homeostasis<sup>7</sup>. Disturbance of their normal regulation interferes with metabolism and our energy household. *H. pylori* eradication increases serum ghrelin levels<sup>8</sup>.

For these reasons, several epidemiological studies have focused on the correlation between *H. pylori* colonization and BMI and obesity. They showed contrasting results, which were based on *H. pylori* status and BMI data,

<sup>1</sup>Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. <sup>2</sup>Internal Medicine, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. <sup>3</sup>The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>4</sup>The Genetics of Obesity and Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>5</sup>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. <sup>6</sup>Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada. <sup>7</sup>Department of Medicine A, University Medicine Greifswald, Greifswald, Germany. <sup>8</sup>Epidemiology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. <sup>9</sup>Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. <sup>10</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Wouter J. den Hollander and Linda Broer contributed equally to this work. Correspondence and requests for materials should be addressed to W.J.d.H. (email: [w.j.denhollander@gmail.com](mailto:w.j.denhollander@gmail.com))

Cohort	RS-I and RS-II	SHIP	SHIP-TREND
Total number (n)	7,977	4,081	986
Age (years), mean (sd)	69.0 (9.3)	49.7 (16.3)	50.1 (13.7)
Female sex (%)	4,391 (55.0)	2,073 (50.8)	554 (56.2)
<i>H. pylori</i> titer distribution, median (range)	24.3 (6.2–5587.4)	30.4 (5–500)	16.1 (5–500)
<i>H. pylori</i> positive (cut-off) <sup>1</sup> , %	4,372 (54.8)	2,275 (59.4)	440 (44.8)
<i>H. pylori</i> positive (highest 25% IgG titer) <sup>2</sup> , %	1,994 (25.0)	958 (25.0)	246 (25.0)
<i>H. pylori</i> antigen distribution, median (range)	NA	NA	−0.004 (−0.151, 3.983)
<i>H. pylori</i> antigen (cut-off) <sup>1</sup> , %	NA	NA	255 (26.9)
BMI (kg/m <sup>2</sup> ), mean (sd)	26.7 (3.9)	27.3 (4.7)	27.4 (4.6)
Missing, n (%)	209 (2.6)	11 (0.3)	0 (0.0)
Obesity (BMI ≥ 30), %	1,343 (17.3)	1,042 (25.6)	252 (25.6)
Overweight (BMI ≥ 25), %	5,027 (64.7)	2,690 (66.1)	660 (66.9)
Obesity classes (BMI), %			
Lean, <18.5	79 (1.0)	42 (1.0)	2 (0.2)
Normal weight, 18.5–24.9	2,662 (34.3)	1,338 (32.9)	324 (32.9)
Overweight, 25.0–29.9	3,684 (47.2)	1,648 (40.5)	408 (41.4)
Class I obesity, 30.0–34.9	1,110 (14.3)	775 (19.0)	200 (20.3)
Class II obesity, 35.0–39.9	203 (2.6)	217 (5.3)	42 (4.3)
Class III obesity, ≥40.0	30 (0.4)	50 (1.2)	10 (1.0)
BMI risk score, mean (sd)	43.22 (3.98)		
Missing, n (%)	1,094 (13.7)	257 (6.3)	3 (0.3)
Obesity risk score, mean (sd)	42.58 (3.94)		
Missing, n (%)	1,094 (13.7)	257 (6.3)	3 (0.3)
<i>H. pylori</i> risk score, mean (sd)	3.34 (0.65)		
Missing, n (%)	1,094 (13.7)	257 (6.3)	3 (0.3)

**Table 1.** Baseline characteristics (total cohort n = 13,044). <sup>1</sup>According to manufacturer’s definition. <sup>2</sup>According to phenotype definition. NA, not applicable.

but did not include genetic information. A recent genome-wide association study (GWAS) identified two genetic loci associated with anti-*H. pylori* IgG titers<sup>9</sup>. Numerous GWAS have identified many genetic loci associated with BMI variation and/or obesity risk<sup>10</sup>. Combining these results into risk scores enables a Mendelian randomization study for association between *H. pylori* serology and BMI. Mendelian randomization is a technique that aims at unbiased detection of causal effects<sup>11</sup>.

We aimed to assess the relationship between *H. pylori* seroprevalence and obesity using both epidemiological and genetic data of two population-based cohort studies. Results of cross-sectional and genetic analyses were compared. In addition, we performed a meta-analysis of data derived from both cohorts.

## Results

**Baseline characteristics.** In total, 13,044 participants were initially included in this study. Table 1 summarizes the baseline characteristics of each cohort. In 220 subjects (1.7%) no data on BMI was available. Data on *H. pylori* titer was lacking in 252 individuals (1.9%) of SHIP. The total population included in the cross-sectional analyses consisted of 12,572 (96.4%) subjects. According to the predefined phenotypic seroprevalence, a total of 3,147 (25.0%) subjects were considered as cases, and 9,425 (75%) as controls.

Genotyping data was available for 6,883 (86.3%) subjects of RS, for 3,824 (93.7%) subjects of SHIP, and for 983 (99.7%) of SHIP-TREND, leaving a total population for analysis of 11,690 (89.6%) subjects. Table 1 summarizes the mean gene risk score for each cohort with respect to the correlation between BMI, obesity, and *H. pylori*. Linear regression analysis within RS focusing on the BMI gene score and BMI revealed a beta of 0.10 kg/m<sup>2</sup> per additional BMI-increasing allele (95% CI 0.07–0.12,  $p = 5.29 \cdot 10^{-16}$ ). Logistic regression analysis focusing on the obesity gene score and obesity (BMI ≥ 30 kg/m<sup>2</sup>) revealed an OR of 1.04 per additional obesity risk allele (95% CI 1.02–1.05,  $p = 1.09 \cdot 10^{-4}$ ). The *H. pylori* gene score was significantly associated with *H. pylori* positivity (OR 1.39, 95% CI 1.27–1.51;  $p = 3.46 \cdot 10^{-13}$ ). The proportion of variance of BMI, obesity, and *H. pylori* explained by the genetic risk scores ranged from 0.3% for obesity, 0.5% for *H. pylori* and 1% for BMI per 1 unit increase in score.

**Cross-sectional analyses.** Cross-sectional analyses revealed an association between *H. pylori* titer and BMI in RS and SHIP (Supplementary Table S1), however with opposite direction. Meta-analysis of all three cohorts showed no association between *H. pylori* titer and BMI, nor between *H. pylori* positivity and BMI (Table 2). *H. pylori* titer, adjusted for age and sex, was negatively associated with obesity (OR 0.99; 95% CI 0.99–1.00,  $p = 0.03$ ) and with obesity classes (Beta  $-6.91 \cdot 10^{-3}$ ; 95% CI  $-1.38 \cdot 10^{-4}$ ,  $-5.49 \cdot 10^{-7}$ ,  $p = 0.048$ ) (Table 2).

Cross-sectional analyses regarding fecal *H. pylori* status and BMI/obesity showed no association (Supplementary Table S2).

Model	Cohort			Meta-analysis	
	RS	SHIP	SHIP-TREND	Beta kg/m <sup>2</sup> (95% CI)	p-value
<b>BMI~<i>H. pylori</i></b>					
<i>Hp</i> titer - crude	–	+	+	1.19•10 <sup>-3</sup> (–1.61•10 <sup>-3</sup> ; 3.99•10 <sup>-3</sup> )	0.39
<i>Hp</i> titer - adjusted <sup>1</sup>	–	+	–	–3.09•10 <sup>-4</sup> (–6.46•10 <sup>-4</sup> ; 2.81•10 <sup>-5</sup> )	0.07
<i>Hp</i> positivity - crude	–	+	+	0.37 (–0.48; 1.22)	0.40
<i>Hp</i> positivity - adjusted <sup>1</sup>	–	+	–	0.04 (–0.34; 0.41)	0.84
<b>Obesity<sup>2</sup>~<i>H. pylori</i></b>				<b>OR (95% CI)</b>	
<i>Hp</i> titer - crude	–	+	+	1.00 (0.99; 1.00)	0.72
<i>Hp</i> titer - adjusted <sup>1</sup>	–	+	–	1.00 (0.99; 1.00)	<b>0.03</b>
<i>Hp</i> positivity - crude	–	+	+	1.04 (0.78; 1.39)	0.78
<i>Hp</i> positivity - adjusted <sup>1</sup>	–	+	–	0.95 (0.86; 1.06)	0.37
<b>Obesity classes<sup>3</sup>~<i>H. pylori</i></b>				<b>Beta (95% CI)</b>	
<i>Hp</i> titer - crude	–	+	+	2.28•10 <sup>-4</sup> (–2.91•10 <sup>-4</sup> ; 7.48•10 <sup>-4</sup> )	0.39
<i>Hp</i> titer - adjusted <sup>1</sup>	–	+	–	–6.91•10 <sup>-5</sup> (–1.38•10 <sup>-4</sup> ; –5.49•10 <sup>-7</sup> )	<b>0.05</b>
<i>Hp</i> positivity - crude	–	+	+	0.06 (–0.10; 0.22)	0.49
<i>Hp</i> positivity - adjusted <sup>1</sup>	–	+	–	–0.02 (–0.05; 0.02)	0.36

**Table 2.** Cross-sectional analyses regarding serologic *H. pylori* status and BMI/obesity – meta-analysis. <sup>1</sup>Adjusted for sex and age. <sup>2</sup>Obesity defined as BMI  $\geq 30$  kg/m<sup>2</sup>. <sup>3</sup>Lean: BMI < 18.5 kg/m<sup>2</sup>; normal-weight: BMI  $\geq 18.5$  and < 25 kg/m<sup>2</sup>; overweight: BMI  $\geq 25$  and < 30 kg/m<sup>2</sup>; class I obesity: BMI  $\geq 30$  and < 35 kg/m<sup>2</sup>; class II obesity: BMI  $\geq 35$  and < 40 kg/m<sup>2</sup>, class III obesity: BMI  $\geq 40$  kg/m<sup>2</sup>. ‘–’ means a negative Beta or OR < 0.1. ‘+’ means a positive Beta or OR > 0.1.

**Mendelian randomization.** The BMI gene score was not associated with *H. pylori* titer or positivity (Table 3). Supplementary Table S3 shows the results of each cohort. Crude analysis showed a positive association between obesity gene score and *H. pylori* titer (Beta 0.76; 95% CI 0.02–1.50,  $p = 0.04$ ) (Table 3). *H. pylori* gene score was not associated with BMI, neither with obesity nor obesity classes (Table 4 and Supplementary Table S4). Also, no associations were observed regarding fecal *H. pylori* status and the BMI or obesity gene score (Supplementary Table S5).

## Discussion

This study included a meta-analysis of 13,044 subjects from two large population-based cohorts. This analysis did not demonstrate an association between *H. pylori* colonization and BMI, neither when examined by means of serology, nor by fecal antigen, or Mendelian randomization. *H. pylori* serology, adjusted for age and sex, was negatively associated with obesity (BMI  $\geq 30$  kg/m<sup>2</sup>), and obesity classes. However, these effects were small. Active *H. pylori* colonization, determined by a positive fecal antigen test, was also not positively or negatively associated with obesity. While the unadjusted and adjusted effect estimates for the obesity gene score on anti-*H. pylori* IgG titer were positive, this association did not remain statistically significant after adjustment for age and sex. So, the use of a Mendelian randomization method did not show a causal bi-directional link between *H. pylori* serology and BMI or obesity.

Our meta-analysis of *H. pylori* status as determined by serology showed a small negative association with both obesity and obesity classes. Considering both the small effect estimates, and opposite directions in the individual cohorts, we consider these associations as clinically irrelevant. Prior epidemiological studies have shown either negative<sup>12</sup>, or positive<sup>13,14</sup>, or no association<sup>15,16</sup> between *H. pylori* and BMI or obesity. The latter findings are most in line with our findings. A recent review of studies reporting data on *H. pylori* and obesity prevalence rates in developed countries, showed an inverse correlation ( $r = -0.29$ ,  $p < 0.001$ ) between *H. pylori* colonization and obesity and overweight<sup>17</sup>. In total, data of 99,463 subjects from 49 studies were pooled. Prevalence rates for *H. pylori*, but also for overweight and obesity were highly variable between included studies. Nevertheless, no additional analyses were performed to examine whether this correlation was related to potential significant confounders such as age. Age is an important confounder as it is positively correlated with *H. pylori* colonization<sup>18</sup>, and negatively with obesity<sup>18</sup>. This may explain the negative correlation between *H. pylori* and obesity reported in the systematic review. Other studies have observed weight gain following successful *H. pylori* eradication<sup>19–23</sup>. A clinical trial from Japan randomized 1,558 *H. pylori*-positive adults to either antibiotic treatment or placebo with a subsequent follow-up of 6 months. *H. pylori* eradication was associated with a mean weight gain of 0.6 kg (95% CI 0.31, 0.88) and an increase in BMI of 0.2 kg/m<sup>2</sup><sup>19</sup>. The simultaneous improvement of dyspepsia symptoms in the eradication group may have stimulated the appetite and subsequently caused the weight gain by increased food intake. Others have suggested that circulating meal-associated leptin and ghrelin levels, which changed after *H. pylori* eradication, gave rise to the increased BMI. US investigators observed an increase in both post-prandial levels of leptin and ghrelin a median seven months following *H. pylori* eradication in a group of 21 patients<sup>24</sup>. In addition, BMI significantly increased after over 18 months of follow-up, while no change was observed in those who were *H. pylori*-negative at baseline. Although these studies provided evidence that *H. pylori* eradication may result in weight gain, it does not imply that there is an absolute difference in BMI between *H. pylori*-negative and positive subjects. Both our cross-sectional as well as Mendelian randomization results suggest that *H. pylori*-colonized and *H. pylori*-negative subjects have similar BMI. The congruence between the

Model	Cohort			Meta-analysis	
	RS	SHIP	SHIP-TREND	Beta (95% CI)	p-value
<b><i>H. pylori</i> titer~BMI gene score</b>					
BMI gene score – crude	+	+	+	0.12 (–0.63; 0.87)	0.76
BMI gene score – adjusted <sup>1</sup>	+	–	+	0.03 (–0.71; 0.77)	0.95
BMI gene score – adjusted <sup>2</sup>	+	–	+	0.04 (–0.71; 0.78)	0.92
<b><i>H. pylori</i> positivity~BMI gene score</b>				<b>OR (95% CI)</b>	
BMI gene score – crude	+	+	–	1.01 (1.00; 1.02)	0.14
BMI gene score – adjusted <sup>1</sup>	+	+	–	1.01 (1.00; 1.02)	0.20
BMI gene score – adjusted <sup>2</sup>	+	+	–	1.01 (1.00; 1.02)	0.15
<b><i>H. pylori</i> titer~Obesity gene score</b>				<b>Beta (95% CI)</b>	
Obesity gene score – crude	+	+	–	0.76 (0.02; 1.50)	<b>0.04</b>
Obesity gene score – adjusted <sup>1</sup>	+	+	–	0.73 (–0.00; 1.47)	0.05
Obesity gene score – adjusted <sup>2</sup>	+	+	–	0.71 (–0.03; 1.45)	0.06
<b><i>H. pylori</i> positivity~Obesity gene score</b>				<b>OR (95% CI)</b>	
Obesity gene score – crude	+	+	–	1.01 (1.00; 1.02)	0.12
Obesity gene score – adjusted <sup>1</sup>	+	+	–	1.01 (1.00; 1.02)	0.14
Obesity gene score – adjusted <sup>2</sup>	+	+	–	1.01 (1.00; 1.02)	0.15

**Table 3.** Mendelian randomization *H. pylori* and BMI/obesity gene score – meta-analysis. <sup>1</sup>Adjusted for age and sex. <sup>2</sup>Adjusted for age, sex, and BMI. ‘–’ means a negative Beta or OR < 0.1. ‘+’ means a positive Beta or OR > 0.1.

results of our cross-sectional and Mendelian randomization analyses is important, as the latter is based on an unbiased approach<sup>11</sup>.

One of the strengths of this study was the use of different methods to detect *H. pylori* colonization, by means of both serology and stool antigen. The latter is a reliable method to identify active *H. pylori* colonization. While most prior studies reported data on serology, we were able to show that results for serology and fecal antigen did not differ. In addition, the use of SNP typing data with genetic risk scores for BMI, obesity, and *H. pylori* colonization is unique in this field. The Mendelian randomization method is a powerful control for reverse causation and confounding, which otherwise affects epidemiological studies<sup>11</sup>. It is based on the common disease, common variant hypothesis, which argues that common variants with modest effects underlie many complex traits<sup>25</sup>.

As any method, the Mendelian randomization has its limitations. Although many genetic variants are discovered, these common variants only explain a small proportion of the estimated trait heritability. Regarding the *H. pylori*-gene risk score, we were only able to include two genetic variants, due to the fact that no others (as far as we know) have been discovered so far, and these explain only 0.5% of the variance. Similarly, a recent large-scale consortium study estimates that 97 GWAS loci account for ~2.7% of BMI variation<sup>26</sup>. Data on *H. pylori* eradication was not available in the RS and SHIP cohort. Nevertheless, given the selective indications for this both in The Netherlands and in Germany, we can safely assume that this was a small minority of the total population. Finally, we did not account for socio-economic status in the cross-sectional analyses. Although both populations are similar regarding ethnicity and age distribution, differences in socio-economic status are associated with both *H. pylori* colonization and BMI, and may therefore have influenced our outcome.

In conclusion, this study provides no evidence for a cross-sectional association between *H. pylori* colonization and BMI or obesity in adults. Mendelian randomization revealed no causal relation between *H. pylori* and BMI or obesity.

## Methods

**Study cohorts.** The Rotterdam Study is a large, population based prospective study of elderly individuals of European ancestry consisting of three cohorts (RS-I, RS-II, RS-III), who are residing in a suburb of Rotterdam, the Netherlands. The study design has been described in detail previously<sup>23,27</sup>. Baseline recruitment and measurements for the RS-I study were obtained between 1990 and 1993. The second cohort, RS-II, was set-up in 2000–2001. A third cohort, RS-III, started in 2006 and recruitment ended in December 2008.

The SHIP study comprises two independent prospectively recruited population-based cohorts in Northeastern Germany: SHIP and SHIP-TREND. The study design of SHIP has been described in detail previously<sup>18</sup>. Participants were recruited between October 1997 and May 2001. SHIP-TREND is an independent cohort from the same region. Individuals were recruited between September 2008 and summer 2012<sup>18</sup>. An important characteristic of SHIP is that it attempts to describe health-related conditions with the widest focus possible.

Data from SHIP, SHIP-TREND, RS-I, and RS-II (RS from now on) were used in this study. Written informed consent was obtained from all participants. Both the medical ethics committee of the Erasmus MC University Medical Center Rotterdam and University Medicine Greifswald approved the study. All methods were performed in accordance with the relevant guidelines and regulations, approved by the medical ethics committee.

**Phenotype definition.** Serologic *H. pylori* colonization in individuals from SHIP, SHIP-TREND, and RS was defined by measuring IgG antibody levels in serum using commercial enzyme-linked immunosorbent assay (Pyloriset EIA-G III ELISA; Orion). Seropositivity was defined as an anti-*H. pylori* IgG titer of  $\geq 20$  U/mL

Model	Cohort			Meta-analysis	
	RS	SHIP	SHIP-TREND	Beta (95% CI)	p-value
<b>BMI~<i>H. pylori</i> gene score</b>					
<i>Hp</i> gene score – crude	–	–	–	–0.05 (–0.16; 0.07)	0.43
<i>Hp</i> gene score – adjusted <sup>1</sup>	–	–	–	–0.06 (–0.17; 0.05)	0.31
<i>Hp</i> gene score – adjusted <sup>2</sup>	–	–	–	–0.05 (–0.17; 0.06)	0.37
<b>Obesity3~<i>H. pylori</i> gene score</b>				<b>OR (95% CI)</b>	
<i>Hp</i> gene score – crude	–	+	–	0.98 (0.92; 1.05)	0.60
<i>Hp</i> gene score – adjusted <sup>1</sup>	–	–	–	0.98 (0.91; 1.04)	0.47
<i>Hp</i> gene score – adjusted <sup>2</sup>	+	–	–	0.98 (0.91; 1.05)	0.56
<b>Obesity classes<sup>4</sup>~<i>H. pylori</i> gene score</b>				<b>Beta (95% CI)</b>	
<i>Hp</i> gene score – crude	+	–	–	–0.01 (–0.03; 0.02)	0.54
<i>Hp</i> gene score – adjusted <sup>1</sup>	+	–	–	–0.01 (–0.03; 0.01)	0.37
<i>Hp</i> gene score – adjusted <sup>2</sup>	+	–	–	–0.03 (–0.06; 0.01)	0.15

**Table 4.** Mendelian randomization regarding BMI/obesity and *H. pylori* gene score – meta-analysis.

<sup>1</sup>Adjusted for age and sex. <sup>2</sup>Adjusted for age, sex, and *H. pylori*. <sup>3</sup>Obesity defined as BMI  $\geq 30$  kg/m<sup>2</sup>. <sup>4</sup>Obesity classes defined as lean: BMI  $< 18.5$  kg/m<sup>2</sup>; normal-weight: BMI  $\geq 18.5$  and  $< 25$  kg/m<sup>2</sup>; overweight: BMI  $\geq 25$  and  $< 30$  kg/m<sup>2</sup>; class I obesity: BMI  $\geq 30$  and  $< 35$  kg/m<sup>2</sup>; class II obesity: BMI  $\geq 35$  and  $< 40$  kg/m<sup>2</sup>, class III obesity: BMI  $\geq 40$  kg/m<sup>2</sup>. ‘–’ means a negative Beta or OR  $< 0.1$ . ‘+’ means a positive Beta or OR  $> 0.1$ .

according to the manufacturer’s instructions<sup>28</sup>. Seropositivity is an indicator for current or past colonization. The sensitivity of the Pyloriset EIA-G III ELISA is reported as 97.8%, with a specificity of 58%<sup>29</sup>. To increase specificity and reduce the number of false-positive *H. pylori* infections, we defined subjects with the 25% highest IgG titers as *H. pylori* cases, and those with the 75% lowest IgG titers as controls<sup>9</sup>.

We further assessed the presence of *H. pylori* antigen in stool of subjects from SHIP-TREND by using the *H. pylori* antigen ELISA kit (Immunodiagnosics). For this purpose, 100 mg feces was stored at  $-20^{\circ}\text{C}$ . An optical density (OD)  $\geq 0.025$  at 450 nm was considered evidence of *H. pylori* infection, according to the manufacturer’s recommendation. This test has a sensitivity of 97.7% and specificity of 96.3%. *H. pylori* stool antigen levels and measured anti-*H. pylori* IgG titers are positively correlated (Spearman  $\rho = 0.59$ ,  $p < 0.001$ )<sup>9</sup>.

**Genetic risk score conduction.** For the creation of the genetic risk scores (BMI risk score, obesity risk score, *H. pylori* risk score), we firstly searched the literature for publications of genome-wide association studies (GWAS) for these traits. A list of SNPs that reached genome-wide significance ( $P < 5 \times 10^{-8}$ ) with BMI or binary obesity status in populations of European ancestry was established. Three different strategies were used to optimize the SNP selection procedure using a key word search (e.g. BMI) on i) the National Human Genome Research Institute (NHGRI) GWAS Catalog ([www.genome.gov/gwastudies/](http://www.genome.gov/gwastudies/)) ii) the HuGE Navigator GWAS Integrator ([www.hugenavigator.net/HuGENavigator/gWAHitStartPage.do](http://www.hugenavigator.net/HuGENavigator/gWAHitStartPage.do)) iii) the PubMed database ([www.ncbi.nlm.nih.gov/pubmed](http://www.ncbi.nlm.nih.gov/pubmed)). Using this strategy, 45 independent loci were found to be associated with BMI variation and 48 with binary obesity status. We chose to analyze risk scores for BMI and obesity separately. BMI is a phenotype which results in a relatively clean risk score. In contrast, various different definitions have been used to define obesity, like BMI  $\geq 25$ , or BMI  $\geq 30$ . For this reason we used both phenotypes (e.g. BMI continuous and binary) in our analyses. A genotype score (GS) was calculated by summing the alleles of BMI / obesity / *H. pylori* status-associated SNPs. An unweighted GS was used as previously recommended by Dudbridge *et al.*<sup>30</sup>. Imputed genotypes (1000 G PhaseIV3) were used for the creation of the GS. All GWAS published before June 2014 were included. Per genetic locus, 1 SNP was selected based on the following criteria: 1) SNP genotyped with an imputation quality (R2) of 0.3 or higher in all populations; 2) Preference for A/C or G/T variants to avoid strand issues. A list of all studies and variants considered, as well as the variants selected can be found in Supplementary Tables S6, S7 and S8.

**Statistical analysis.** In total, we used three different approaches to assess the relationship between *H. pylori* status and BMI/obesity. First, cross-sectional analyses were performed to assess the relationship between *H. pylori* colonization and BMI/obesity at time of inclusion, by using linear and logistic regression. Outcomes were defined as continuous BMI, binary obesity (BMI  $\geq 30$  kg/m<sup>2</sup>, with BMI  $< 30$  kg/m<sup>2</sup> as reference group), and obesity classes (lean BMI  $< 18.5$  kg/m<sup>2</sup>; normal-weight BMI  $\geq 18.5$  and  $< 25$  kg/m<sup>2</sup>; overweight BMI  $\geq 25$  and  $< 30$  kg/m<sup>2</sup>; class I obesity BMI  $\geq 30$  and  $< 35$  kg/m<sup>2</sup>; class II obesity BMI  $\geq 35$  and  $< 40$  kg/m<sup>2</sup>, class III obesity BMI  $\geq 40$  kg/m<sup>2</sup>). The latter outcome was defined as a continuous variable with value ‘0’ for lean, and value ‘5’ for class III obesity. Unadjusted effects of *H. pylori* titer or antigen (continuous) and *H. pylori* positivity (binary phenotype) were assessed for each outcome. We additionally adjusted for sex and age. All analyses were done separately for RS, SHIP, and SHIP-TREND. A meta-analysis was performed to observe the combined effect of *H. pylori* colonization on BMI/obesity.

Second, a Mendelian randomization approach was carried out to explore a bi-directional link between *H. pylori* colonization and BMI. Linear regression analysis was used to assess the relationship between BMI gene score and *H. pylori* titer and *H. pylori* positivity. Analyses were first adjusted for sex, age, and additionally for BMI at baseline. The same analyses were done regarding the obesity gene score. Linear regression analysis was

also used to examine the effect of the *H. pylori* gene score with BMI, binary obesity status, and obesity classes, all defined at baseline. Analyses were adjusted for sex, and age, and additionally for *H. pylori* status (binary phenotype). Data of the three cohorts were combined and examined by using meta-analysis approach. A p-value < 0.05 was considered to be statistically significant.

All measures of associations are presented as Odds Ratios (OR) or Beta's with their 95% confidence intervals (CI). Statistical analyses were performed using IBM SPSS Statistics 21.0 for Windows (SPSS IBM, Armonk, New York, USA). Meta-analyses were done with R library meta (R Core Team (2014), R Foundation for Statistical Computing, Vienna, Austria).

**Data availability.** Due to ethical restrictions data are available upon request. Interested researchers may contact our data management team (secretariat.epi@erasmusmc.nl) for access to sensitive data.

## References

- Fontaine, K. R., Redden, D. T., Wang, C., Westfall, A. O. & Allison, D. B. Years of life lost due to obesity. *JAMA* **289**, 187–193 (2003).
- Finkelstein, E. A., Trogon, J. G., Cohen, J. W. & Dietz, W. Annual medical spending attributable to obesity: payer- and service-specific estimates. *Health Aff (Millwood)* **28**, w822–831 (2009).
- McAllister, E. J. *et al.* Ten putative contributors to the obesity epidemic. *Crit Rev Food Sci Nutr* **49**, 868–913 (2009).
- DiBaise, J. K. *et al.* Gut microbiota and its possible relationship with obesity. *Mayo Clinic proceedings* **83**, 460–469 (2008).
- Blaser, M. J. & Falkow, S. What are the consequences of the disappearing human microbiota? *Nature reviews. Microbiology* **7**, 887–894 (2009).
- den Hollander, W. J. *et al.* Intergenerational reduction in *Helicobacter pylori* prevalence is similar between different ethnic groups living in a Western city. *Gut* **64**, 1200–1208 (2015).
- Klok, M. D., Jakobsdottir, S. & Drent, M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. *Obesity reviews: an official journal of the International Association for the Study of Obesity* **8**, 21–34 (2007).
- Nwokolo, C. U., Freshwater, D. A., O'Hare, P. & Randevara, H. S. Plasma ghrelin following cure of *Helicobacter pylori*. *Gut* **52**, 637–640 (2003).
- Mayerle, J. *et al.* Identification of genetic loci associated with *Helicobacter pylori* serologic status. *JAMA* **309**, 1912–1920 (2013).
- Pigeyre, M., Yazdi, F. T., Kaur, Y. & Meyre, D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. *Clin Sci (Lond)* **130**, 943–986 (2016).
- Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human molecular genetics* **23**, R89–98 (2014).
- Vo, H. D. *et al.* Inverse Correlation Between *Helicobacter pylori* Colonization and Obesity in a Cohort of Inner City Children. *Helicobacter* **20**, 64–68 (2015).
- Chen, T. P. *et al.* *Helicobacter Pylori* Infection is Positively Associated with Metabolic Syndrome in Taiwanese Adults: a Cross-Sectional Study. *Helicobacter* **20**, 184–191 (2015).
- Xu, C. *et al.* Prevalence of *Helicobacter pylori* infection and its relation with body mass index in a Chinese population. *Helicobacter* **19**, 437–442 (2014).
- Cho, I. *et al.* *Helicobacter pylori* and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol* **162**, 579–584 (2005).
- Ioannou, G. N., Weiss, N. S. & Kearney, D. J. Is *Helicobacter pylori* seropositivity related to body mass index in the United States? *Aliment Pharmacol Ther* **21**, 765–772 (2005).
- Lender, N. *et al.* Review article: Associations between *Helicobacter pylori* and obesity—an ecological study. *Aliment Pharmacol Ther* **40**, 24–31 (2014).
- Volzke, H. *et al.* Cohort profile: the study of health in Pomerania. *Int J Epidemiol* **40**, 294–307 (2011).
- Lane, J. A. *et al.* Randomised clinical trial: *Helicobacter pylori* eradication is associated with a significantly increased body mass index in a placebo-controlled study. *Aliment Pharmacol Ther* **33**, 922–929 (2011).
- Jang, E. J. *et al.* The influence of the eradication of *Helicobacter pylori* on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. *J Gastroenterol Hepatol* **23**(Suppl 2), S278–285 (2008).
- Yang, Y. J., Sheu, B. S., Chang, W. L., Cheng, H. C. & Yang, H. B. Increased body mass index after *H. pylori* eradication for duodenal ulcer predisposes to erosive reflux esophagitis. *J Clin Gastroenterol* **43**, 705–710 (2009).
- Suto, H. *et al.* The effects of *Helicobacter pylori* eradication on body mass index and dyspeptic symptoms. *Digestion* **79**, 235–242 (2009).
- Hofman, A. *et al.* The Rotterdam Study: objectives and design update. *Eur J Epidemiol* **22**, 819–829 (2007).
- Francois, F. *et al.* The effect of *H. pylori* eradication on meal-associated changes in plasma ghrelin and leptin. *BMC Gastroenterol* **11**, 37 (2011).
- Schork, N. J., Murray, S. S., Frazer, K. A. & Topol, E. J. Common vs. rare allele hypotheses for complex diseases. *Current opinion in genetics & development* **19**, 212–219 (2009).
- Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015).
- Hofman, A. *et al.* The Rotterdam Study: 2016 objectives and design update. *Eur J Epidemiol* **30**, 661–708 (2015).
- Rehberg-Laiho, L. *et al.* Accelerated decline in *Helicobacter pylori* seroprevalence rate during the screen and treat project in Vammala, Finland, as demonstrated in 29- to 45-year-old pregnant women. *APMIS: acta pathologica, microbiologica, et immunologica Scandinavica* **112**, 34–38 (2004).
- Hanvivatvong, O., Pongpanich, A., Thong-Ngam, D., Thammacharoenrach, N. & Kullavanijaya, P. Evaluation of commercial immunoassays for detection of antibody against *Helicobacter pylori* in Thai dyspeptic patients. *Clinical and diagnostic laboratory immunology* **11**, 618–620 (2004).
- Dudbridge, F. Power and predictive accuracy of polygenic risk scores. *PLoS genetics* **9**, e1003348 (2013).

## Acknowledgements

The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam; The Netherlands Organisation for Scientific Research (NWO); The Netherlands Organisation for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); The Netherlands Genomics Initiative (NGI); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. The SHIP project is part of the community medicine research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. None of the funding organizations were involved in study design,

in collection, analysis, and interpretation of data, in writing of the report, or in the decision to submit the article for publication. DM holds a Canada Research Chair in Genetics of Obesity.

### Author Contributions

W.H., L.B., C.S., D.M., A.U., M.L., E.K. contributed to the conception and design, acquisition of data, analyses and interpretation of the data, drafted the article, revised it critically for important intellectual content and gave final approval of the version to be published. C.H., J.M., A.H., G.H. contributed to the conception and design and acquisition of data, revised the article critically for important intellectual content and gave final approval of the version to be published.

### Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-017-14106-4>.

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017